Vanda Pharmaceuticals Inc.
VNDANASDAQHealthcare● Active
$5.93
$-0.10(-1.66%)
Market Cap$356603883
P/E Ratio—
52W High$9.94
52W Low$4.14
Vanda Pharmaceuticals Inc. (VNDA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · VNDA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.22B | $0.20B | $0.19B | $0.25B | $0.27B |
| Cost of Revenue | $0.01B | $0.01B | $0.01B | $0.02B | $0.03B |
| Gross Profit | $0.20B | $0.19B | $0.18B | $0.23B | $0.24B |
| Gross Margin %(computed) | 93.96% | 94.31% | 92.32% | 90.45% | 90.46% |
| Operating Expenses | |||||
| R&D Expenses | $0.11B | $0.07B | $0.08B | $0.09B | $0.08B |
| G&A Expenses | $0.00B | $0.14B | $0.11B | $0.13B | $0.12B |
| Total Operating Expenses | $0.35B | $0.23B | $0.19B | $0.22B | $0.20B |
| Operating Income | ($0.15B) | ($0.04B) | ($0.01B) | $0.01B | $0.04B |
| Operating Margin %(computed) | -69.95% | -20.46% | -7.24% | 2.49% | 15.69% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.14B) | ($0.02B) | $0.01B | $0.01B | $0.04B |
| Income Tax Expense | $0.08B | ($0.00B) | $0.00B | $0.01B | $0.01B |
| Net Income | ($0.22B) | ($0.02B) | $0.00B | $0.01B | $0.03B |
| Net Margin %(computed) | -102.02% | -9.51% | 1.30% | 2.47% | 12.34% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.74 | $-0.32 | $0.04 | $0.11 | $0.60 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B |
| EBITDA | ($0.14B) | ($0.03B) | ($0.01B) | $0.01B | $0.05B |
| EBITDA Margin %(computed) | -64.44% | -16.36% | -5.68% | 3.56% | 16.75% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Vanda Pharmaceuticals Inc. data
About Vanda Pharmaceuticals Inc. (VNDA) Income Statement
Vanda Pharmaceuticals Inc. (VNDA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, VNDA reported revenue of $0.22B, gross profit of $0.20B (gross margin 93.96%), and net income of ($0.22B) — a net profit margin of -102.02%.
Frequently asked questions
VNDA · 4 questionsVanda Pharmaceuticals Inc. (VNDA) reported revenue of $0.22B for 2025, up 8.7% year-over-year.
VNDA revenueVNDA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08